Skip to main content
MYRIAD GENETICS INC logo

MYRIAD GENETICS INC — Investor Relations & Filings

Ticker · MYGN ISIN · US62855J1043 LEI · 52990044IHUOUMETT163 US Human health and social work activities
Filings indexed 1,308 across all filing types
Latest filing 2026-05-06 Interim / Quarterly Rep…
Country US United States of America
Listing US MYGN

About MYRIAD GENETICS INC

https://myriad.com/

Myriad Genetics is a genetic testing and precision medicine company that develops and commercializes molecular diagnostic tests. The company's tests provide personalized and actionable insights by analyzing an individual's genetic and genomic information. These insights are used to assess the risk of developing hereditary diseases, guide treatment strategies, and inform preventative healthcare decisions. Myriad's portfolio addresses several clinical areas, including oncology, women's health, and mental health. Key offerings include the MyRisk™ test for hereditary cancer risk, Prolaris® for prostate cancer aggressiveness, EndoPredict® for breast cancer recurrence, the Foresight® and Prequel® prenatal screens, and the GeneSight® test to guide mental health medication selection. The company aims to empower patients and healthcare providers with critical information to improve health outcomes.

Recent filings

Filing Released Lang Actions
10-Q - MYRIAD GENETICS INC (0000899923) (Filer)
Interim / Quarterly Report
2026-05-06 English
8-K
Regulatory Filings
2026-05-05 English
ARS - MYRIAD GENETICS INC (0000899923) (Filer)
Annual Report
2026-04-14 English
DEFA14A
Proxy Solicitation & Information Statement
2026-04-14 English
DEF 14A - MYRIAD GENETICS INC (0000899923) (Filer)
Proxy Solicitation & Information Statement
2026-04-14 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-04-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.